[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Inha University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100608208","relationship-between-swallowing-dynamics-and-suprahyoid-muscle-activity-in-sarcopenic-dysphagia-100608208",false,"NCT07198568","Relationship Between Swallowing Dynamics and Suprahyoid Muscle Activity in Sarcopenic Dysphagia","Inclusion Criteria:\n\n* 65 years of age or older who underwent VFSS to evaluate the presence of dysphagia\n* Patient who diagnosed with sarcopenia based on the cutoff values of the Asian Working Group for Sarcopenia (AWGS) 2019\n* Cognitive ability to follow instructions for Videofluoroscopic swallowing study, surface electromyography.\n\nExclusion Criteria:\n\n* History of cerebral hemorrhage or cerebral infarction\n* History of neuromuscular diseases that could lead to dysphagia such as Parkinson's disease, amyotrophic lateral sclerosis, Guillain-Barre disease\n* History of Tracheostomy\n* History of oropharyngeal cancer\n* History of esophageal structural disease that could lead to dysphagia\n* History of connective tissue disease\n* History of cervical surgical procedure\n* Cognitive impairment who cannot follow instructions for Videofluoroscopic swallowing study, surface electromyography","ALL","65 Years",{"count":18,"type":19},50,"ESTIMATED","OBSERVATIONAL","Sarcopenic dysphagia is defined as swallowing difficulty among the elderly due to the loss of whole body skeletal and swallowing muscle mass and function. However, the pathophysiology and dynamics of swallowing in sarcopenic dysphagia have been poorly investigated. Therefore, the present study aims to investigate the characteristics of sarcopenic dysphagia using the Videofluoroscopic study (VFSS) focusing on each phase of dysphagia, and surface Electromyography (surface EMG) to assess suprahyoid muscle activity.\n\nIn sarcopenic dysphagia, impairments will occur in both the oral and pharyngeal phases, particularly affecting bolus formation, premature bolus spillage and laryngeal elevation during swallowing due to the loss of swallowing muscle mass and function. These changes will be considered to have led to an change of duration and amplitude of suprahyoid muscle activity measured via surface EMG.",[23,24],"Sarcopenia in Elderly","Dysphagia","RECRUITING","2026-03-04",{"date":28,"type":29},"2026-03-06","ACTUAL",{"date":31,"type":29},"2024-06-03",{"date":33,"type":19},"2026-04",{"name":35,"class":36},"Inha University Hospital","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":20,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100619674","ai-based-prediction-of-atrial-fibrillation-in-esus-patients-with-icm-100619674","NCT07347691","AI-Based Prediction of Atrial Fibrillation in ESUS Patients With ICM","Predicting Atrial Fibrillation in Patients With Post-implantable Cardiac Monitor Implementation : A Prospective, Long-term Follow-up Study Using Comprehensive AI ECG Analysis : Multicenter Prospective Study","SMART-ESUS","Inclusion Criteria:\n\n* Patients aged 30 years or older.\n* Patients diagnosed with Embolic Stroke of Undetermined Source (ESUS) who have undergone or are scheduled for Implantable Cardiac Monitor (ICM) implantation.\n* Patients who have undergone at least one 12-lead ECG examination within 2 weeks before or after the date of ICM implantation.\n* Patients maintaining Sinus Rhythm on ECG at the time of enrollment.\n* Patients who have voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients diagnosed with Atrial Fibrillation (AF) at least once prior to the date of enrollment.\n* Patients whose ICM battery status is at Elective Replacement Interval (ERI), making recording impossible.\n* Patients whose ECGs cannot be analyzed by the AI algorithm (SmartECG-AF) due to severe artifacts or noise, or are incompatible with digital analysis.","30 Years",{"count":48,"type":19},92,"12 Months","This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the predictive value of an Artificial Intelligence ECG analysis tool, named SmartECG-AF.\n\nParticipants will be classified into two groups based on the AI analysis: a \"High Risk\" group and a \"Low to Intermediate Risk\" (control) group. The study aims to compare the incidence rate of atrial fibrillation (AF) events over time between these two groups. Additionally, the study will analyze the relationship between the AI-predicted risk levels and the occurrence of major cardiovascular events during the follow-up period.",[52],"Embolic Stroke of Undetermined Source",[54,55,56,57,58,59],"Implantable Cardiac Monitor","Artificial Intelligence","Deep Learning","Electrocardiography","Risk Prediction","Cryptogenic Stroke","2026-01-09",{"date":62,"type":29},"2026-01-16",{"date":64,"type":29},"2025-11-19",{"date":66,"type":19},"2028-05",{"name":35,"class":36},5,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100613765","phase-4-dronedarone-rhythm-intervention-for-early-atrial-fibrillation-100613765","NCT07270848","Dronedarone Rhythm Intervention for Early Atrial Fibrillation","A Multicenter Prospective Study on the Efficacy, Safety, and Quality of Life Improvements of Dronedarone for Early Rhythm Control in Atrial Fibrillation","DRIVE-AF","Inclusion Criteria:\n\n* Participants who have voluntarily provided written informed consent to participate.\n* Adults aged 19 years or older.\n* Life expectancy of at least 1 year.\n* Diagnosis of atrial fibrillation within the past 1 year.\n* Participants with an indication for antiarrhythmic drug therapy (Dronedarone or Class Ic agents).\n\nExclusion Criteria:\n\n* History of failure with prior antiarrhythmic drug therapy.\n* Confirmed severe structural heart disease (e.g., heart failure with reduced ejection fraction \\[LVEF \\\u003C= 40%\\], moderate or severe mitral stenosis, mechanical heart valve replacement, or dilated cardiomyopathy).\n* Diagnosis of permanent atrial fibrillation.\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m\\^2 or on dialysis) or severe hepatic impairment (Child-Pugh class B or higher) that restricts the use of antiarrhythmic drugs.\n* Known contraindications to dronedarone or Class Ic antiarrhythmic drugs.\n* Participation in another clinical trial within 3 months prior to randomization.\n* Participants who do not agree to refrain from participating in another clinical trial within 14 days after their participation in this study ends.\n* Pregnant or breastfeeding women, or women of childbearing potential who do not agree to use effective contraception during the study.\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for study participation.","19 Years",{"count":79,"type":19},1898,"INTERVENTIONAL",[82],"PHASE4","The purpose of this study is to compare two commonly used types of medicine for treating atrial fibrillation (also called AF), a condition that causes an irregular heart rhythm. This study is for adults who have been diagnosed with AF within the past year.\n\nResearchers want to find out which medicine is more effective, safer, and provides a better quality of life for patients needing to control their heart rhythm.\n\nParticipants who agree to join the study will be randomly assigned (like flipping a coin) to one of two groups:\n\nGroup 1: Will receive the medicine Dronedarone.\n\nGroup 2: Will receive a standard medicine from the 'Class Ic' group (such as flecainide or propafenone).\n\nThe study will follow participants for at least 12 months. Researchers will compare how well each medicine works to prevent AF from coming back. They will also carefully track any side effects and changes in participants' quality of life during the study.",[85],"Atrial Fibrillation (AF)",[87,88,89,90,91,92],"Atrial Fibrillation","Dronedarone","Flecainide","Propafenone","Antiarrhythmic Drugs","Rhythm Control","NOT_YET_RECRUITING","2025-12-15",{"date":96,"type":29},"2025-12-22",{"date":98,"type":19},"2026-01-01",{"date":100,"type":19},"2028-12",{"name":35,"class":36},16,""]